Biomarkers for antidepressant efficacy of electroconvulsive therapy

• Verfasst von: Kranaster, Laura [VerfasserIn]
• Verfasst von: Hoyer, Carolin [VerfasserIn]
• Verfasst von: Aksay, Suna Su [VerfasserIn]
• Verfasst von: Bumb, Jan Malte [VerfasserIn]
• Verfasst von: Ozbalci, Cagakan [VerfasserIn]
• Verfasst von: Janke, Christoph [VerfasserIn]
• Verfasst von: Thiel, Manfred [VerfasserIn]
• Verfasst von: Sartorius, Alexander [VerfasserIn]
• Titel: Biomarkers for antidepressant efficacy of electroconvulsive therapy
• Titelzusatz: an exploratory cerebrospinal fluid study
• Verf.angabe: Laura Kranaster, Carolin Hoyer, Suna S. Aksay, J. Malte Bumb, Norbert Müller, Peter Zill, Markus J. Schwarz, Natalie Moll, Beat Lutz, Laura Bindila, Inga Zerr, Matthias Schmitz, Kaj Blennow, Henrik Zetterberg, Dieter Haffner, Maren Leifheit-Nestler, Cagakan Ozbalci, Christoph Janke, Manfred Thiel, Alexander Sartorius
• E-Jahr: 2018
• Jahr: November 2018
• Umfang: 10 S.
• Fussnoten: Gesehen am 24.03.2021
• Titel Quelle: Enthalten in: Neuropsychobiology
• Ort Quelle: Basel : Karger, 1975
• Jahr Quelle: 2018
• Band/Heft Quelle: 77(2018), 1, Seite 13-22
• ISSN Quelle: 1423-0224
• DOI: doi:10.1159/000491401
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1752332741

Abstract

Background: No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. Method: Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. Results: Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. Limitations: The sample size is small and the ­distribution of responders and non-responders is uneven. Conclusions: It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.